Skip to content
Strides Pharma Science logo

Strides Pharma Science

STAR NSE
₹1,014.20 −23.10 (−2.23%)
P/E
15.24
View as Markdown
MCP
Close 4 Nov 2026 ₹1,014.20 +54.75 +5.71% 1Y
Start ₹959.45

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
18.30%
Debt to Equity
0.57
EPS (TTM)
₹66.56
Book Value
₹370.66
Market Cap
—
P/E (TTM)
15.24
P/B
2.74
ROE
20.00%
Dividend Yield
0.48%
EBITDA
₹1,076 Cr
52W High
₹1,260.90
52W Low
₹768.65
Day Range
₹1,010.00 – ₹1,047.80
Volume
1,84,833

Peer Comparison

Healthcare › Pharmaceuticals

Strides Pharma Science peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Strides Pharma Science (this company)
₹1,014.2015.24₹9,485 Cr2.740.48%20.00%18.30%₹5,004 Cr₹634 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.570.53%17.40%18.05%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

50 Average

Data confidence 100/100

pledge:34%

Category scores

Quality
54
Average
Returns, margins, earnings quality 22% weight
Valuation
85
Strong
Cheap vs sector & own history 24% weight
Growth
30
Poor
Sales & profit trajectory 9% weight
Financial Health
18
Poor
Solvency, leverage, coverage 9% weight
Momentum
28
Poor
Trend strength, vol-adjusted 12% weight
Ownership
57
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has delivered good profit growth of 20.1% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 57.0%

Weaknesses

4
  • Stock is trading at 3.02 times its book value
  • The company has delivered a poor sales growth of 7.94% over past five years.
  • Promoter holding is low: 29.0%
  • Promoters have pledged 33.8% of their holding.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1261
OscillatorsBearish261
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
38.51
Neutral
MACD (12,26,9)
−17.85
Bearish
SMA (50)
1,097.16
Bearish
SMA (200)
1,020.41
Bearish

As of

Analyst Rating

Based on 1 analysts
BUY100%

1 of 1 analyst rates Buy, 0 Hold, 0 Sell.

As of

BUY
1
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+5.44%
5Y+7.94%
3Y+9.63%
1Y+6.44%
TTM+8.05%

Net profit

Net profit growth by window
10Y+19.73%
5Y+17.38%
3YTurned to profit
1Y−84.02%
TTM+79.10%

Operating cash flow

Operating cash flow growth by window
10Y+25.42%
5Y+7.89%
3Y+151.86%
1Y+2.78%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+5.97 pp
5Y+2.85 pp
3Y+15.11 pp
1Y+1.45 pp
TTM+0.77 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹2,755 Cr
Mar 2018₹2,845 Cr
Mar 2019₹2,178 Cr
Mar 2020₹2,752 Cr
Mar 2021₹3,316 Cr
Mar 2022₹3,070 Cr
Mar 2023₹3,688 Cr
Mar 2024₹3,890 Cr
Mar 2025₹4,565 Cr
Mar 2026₹4,859 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹446 Cr
Mar 2018₹684 Cr
Mar 2019₹330 Cr
Mar 2020₹31.00 Cr
Mar 2021₹258 Cr
Mar 2022−₹474 Cr
Mar 2023−₹212 Cr
Mar 2024−₹94.00 Cr
Mar 2025₹3,598 Cr
Mar 2026₹575 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹1,059 Cr −1.5% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk high

Strides Pharma Science (market cap ₹10,347 Cr, PE 18.1x) has delivered strong profit growth over the past 3-5 years with a notable 3-year ROE of 57%, but faces headwinds from decelerating sales growth (TTM at 6%) and a sharp TTM profit decline of -84%. Promoter pledging at 27.3% adds governance risk to an otherwise improving return profile.

Bull Case 7
  • Strong 3-year ROE of 57% indicates efficient capital allocation and high returns on shareholder equity
  • Compounded profit growth of 71% CAGR over 3 years demonstrates significant earnings recovery
  • 5-year compounded profit growth of 21% CAGR reflects sustained long-term earnings expansion
  • Stock CAGR of 76% over 3 years suggests strong market re-rating driven by improving fundamentals
  • PE ratio of 18.1x is reasonable for a pharma company with 20%+ ROE in the last year
  • 10-year compounded profit growth of 16% CAGR shows the business has scaled profitability over a full cycle
  • Dividend yield of 0.35% indicates the company has initiated shareholder returns alongside growth
Bear Case 8
  • TTM compounded profit declined -84%, signalling a sharp and severe earnings reversal in the most recent period
  • Promoters have pledged 27.3% of their holding, raising corporate governance and forced-selling risk
  • 5-year sales CAGR of only 7.94% reflects poor top-line momentum for a mid-cap pharma company
  • Stock trades at 3.34x book value, which is elevated given the recent earnings collapse
  • TTM sales growth has decelerated to just 6%, below the 10-year average of 5% CAGR on a compounded basis
  • Tax rate appears low, which may not be sustainable and could compress future net margins if normalized
  • 10-year stock CAGR of only 8% suggests long-term wealth creation has been inconsistent despite recent rally
  • Debt-to-equity ratio is undisclosed, limiting visibility into the company's leverage and financial risk profile

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: A quiet period for Strides Pharma with no material positive or negative catalysts. The Pivot Path divestiture is a minor portfolio restructuring event. The STAR ETF news is unrelated to the company. No clear directional trend emerging from recent newsflow.

Neutral 2
  • Sells Pivot Path stake Jun 27

    Strides Pharma sold its majority stake in Pivot Path to Ascent Capital for Rs 1,000 million. Pivot Path will be reclassified as an associate company.

  • Unrelated STAR ETF launched Jun 9

    BlackRock launched the iShares Space Technologies UCITS ETF under the ticker STAR on Jun 9, 2026, tracking space technology stocks. This is unrelated to Strides Pharma and concerns only a shared ticker symbol in European markets.

Quarterly Results

₹ Cr
STAR quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
930
999
1,006
1,044
1,054
1,167
1,154
1,190
1,120
1,221
1,195
1,323
1,265
1,430
Expenses
796
889
876
874
866
983
943
973
902
990
959
1,084
1,037
1,179
Operating Profit
134
111
129
169
188
184
210
218
218
231
236
240
228
251
OPM %
14%
11%
13%
16%
18%
16%
18%
18%
19%
19%
20%
18%
18%
18%
Other Income
3
−129
60
−27
3,299
25
4
−12
0
18
104
3
68
—
Interest
76
79
70
71
73
74
52
50
47
46
43
42
41
47
Depreciation
60
60
49
49.76
47
50.52
48
49
49
50
51
53
56
57
PBT
0
−157
70
23
3,369
86
114
106
122
154
246
148
200
150
Tax %
3025%
−5%
23%
55%
1%
16%
21%
20%
13%
14%
15%
13%
17%
11%
Net Profit
−9
−149
54
10
3,350
72
90
86
106
132
208
129
165
134
EPS (₹)
−0.79
−14.54
5.4
1.98
365
7.81
9.54
8.91
10.8
13.84
21.93
13.77
17.02
—

Sep 2026: from the results filed on 29 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
STAR profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,196
2,861
2,755
2,845
2,178
2,752
3,316
3,070
3,688
3,890
4,565
4,859
5,004
Expenses
967
2,486
2,228
2,448
1,982
2,338
2,779
3,201
3,544
3,362
3,763
3,933
4,070
Operating Profit
229
374
527
398
197
414
537
−131
145
528
803
925
935
OPM %
19%
13%
19%
14%
9%
15%
16%
−4.3%
3.9%
14%
18%
19%
19%
Other Income
874
63
291
643
303
−43
109
−112
92
−100
3,313
124
193
Interest
47
168
183
196
79
156
150
177
261
280
249
179
172
Depreciation
64
131
126
154
117
174
206
233
243
214
192
202
210
PBT
992
137
509
690
303
42
289
−653
−268
−65
3,675
668
746
Tax %
15%
31%
12%
1%
−9%
27%
11%
−27%
−21%
45%
2%
14%
—
Net Profit
844
95
446
684
330
31
258
−474
−212
−94
3,598
575
634
EPS (₹)
142
12.15
44.71
74.25
36.27
4.06
29.93
−51.25
−22.44
−7.68
390
60.34
66.56
Div. Payout %
76%
41%
10%
3%
8%
345%
8%
0%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
1%
8%
—

Balance Sheet

₹ Cr
STAR balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
60
89
89
90
90
90
90
90
90
92
92
92
Reserves
1,085
2,569
2,659
2,374
2,559
2,438
2,687
2,269
2,122
2,034
2,460
3,015
Borrowings
892
3,542
3,700
2,520
3,221
2,235
2,348
3,025
3,030
2,517
1,880
1,758
Other Liabilities
438
1,211
1,598
1,601
1,937
1,369
1,844
1,556
1,352
1,157
1,498
1,941
Total Liabilities
2,475
7,410
8,046
6,585
7,807
6,131
6,969
6,940
6,594
5,799
5,929
6,807
Fixed Assets
701
2,679
2,980
2,977
3,648
2,099
2,219
2,347
2,311
1,865
1,899
2,101
CWIP
171
815
780
620
453
413
447
291
151
162
207
447
Investments
630
1,341
1,525
588
702
549
697
540
490
303
409
291
Other Assets
972
2,576
2,762
2,400
3,005
3,070
3,605
3,762
3,642
3,470
3,414
3,967
Total Assets
2,475
7,410
8,046
6,585
7,807
6,131
6,969
6,940
6,594
5,799
5,929
6,807

Cash Flow

₹ Cr
STAR cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
83
73
288
187
60
205
481
−258
44
701
684
703
Investing
50
−2,205
−1,222
570
−145
1,321
−522
−119
302
−150
−90
−173
Financing
−421
2,944
338
−1,016
194
−1,709
−16
421
−214
−693
−643
−453
Net Cash Flow
−288
812
−596
−259
110
−184
−56
45
133
−142
−48
76
Free Cash Flow
−157
−293
−386
−212
−256
58
188
−326
−43
672
505
291
CFO/EBITDA
61
40
66
61
59
60
60
199
−30
128
77
84

Ratios

STAR financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
119
132
132
113
165
124
122
144
129
107
96
97
Inventory Days
135
149
209
146
294
254
329
285
257
235
236
305
Days Payable
153
188
221
188
299
259
323
260
220
178
190
244
Cash Conversion Cycle
102
92
120
71
160
119
128
168
165
164
141
157
Working Capital Days
−91
6
−122
−4
−70
−70
−22
−28
−11
−19
24
38
ROCE %
57%
8%
11%
16%
2%
5%
8%
−5%
0%
7%
15%
18%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Strides Pharma Science insights

75 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 29.00%
  • FIIs 27.98%
  • Public 19.68%
  • DIIs 15.51%
  • Others 7.82%
  • Government 0.01%

33.79% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Strides Pharma Science

What does Strides Pharma Science Ltd do?
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. The company's pharmaceutical products are sold in over 100 countries.
Where is Strides Pharma Science Ltd (STAR) listed?
Strides Pharma Science Ltd trades as STAR on the NSE and under code 532531 on the BSE.
Which sector does Strides Pharma Science Ltd belong to?
Strides Pharma Science Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Strides Pharma Science Ltd?
Strides Pharma Science Ltd trades at a PE ratio of 15.24 as of 4 Nov 2026, on earnings per share of ₹66.56, against a book value of ₹370.66 per share.
What is the 52-week high and low of Strides Pharma Science Ltd?
Over the last 52 weeks Strides Pharma Science Ltd has traded between ₹768.65 and ₹1,260.9 as of 4 Nov 2026.
Does Strides Pharma Science Ltd pay dividends?
Strides Pharma Science Ltd has a dividend yield of 0.48%.
What is the Return on Equity (ROE) of Strides Pharma Science Ltd?
Strides Pharma Science Ltd reported a return on equity of 20.00%. Its debt-to-equity ratio is 0.57.

Company Information

Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. The company's pharmaceutical products are sold in over 100 countries. The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.

Website strides.com
CEO Mr. Arun Kumar Pillai B.Com.
Employees 3,301
Listed 2 Feb 2000
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/STAR.md for Strides Pharma Science Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month